Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
3.170
+0.090 (2.92%)
At close: May 15, 2026, 4:00 PM EDT
3.190
+0.020 (0.63%)
After-hours: May 15, 2026, 5:12 PM EDT
Lisata Therapeutics Revenue
Lisata Therapeutics had revenue of $170.00K in the twelve months ending March 31, 2026, down -83.00% year-over-year. In the year 2025, Lisata Therapeutics had annual revenue of $170.00K, down -83.00%.
Revenue (ttm)
$170.00K
Revenue Growth
-83.00%
P/S Ratio
163.64
Revenue / Employee
$8,095
Employees
21
Market Cap
28.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.00K | -830.00K | -83.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 22.49M | 4.55M | 25.36% |
| Dec 31, 2014 | 17.94M | 3.27M | 22.29% |
| Dec 31, 2013 | 14.67M | 338.60K | 2.36% |
| Dec 31, 2012 | 14.33M | 4.28M | 42.58% |
| Dec 31, 2011 | 10.05M | -59.77M | -85.61% |
| Dec 31, 2010 | 69.82M | 58.26M | 503.72% |
| Dec 31, 2009 | 11.57M | 11.48M | 13,743.62% |
| Dec 31, 2008 | 83.54K | -148.12K | -63.94% |
| Dec 31, 2007 | 231.66K | 185.94K | 406.66% |
| Dec 31, 2006 | 45.72K | 10.46K | 29.67% |
| Dec 31, 2005 | 35.26K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuphoria Therapeutics | 14.99M |
| Barinthus Biotherapeutics | 14.97M |
| Kyntra Bio | 7.44M |
| IGC Pharma | 1.11M |
| Senti Biosciences Holdings | 22.00K |
LSTA News
- 11 days ago - Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 2 months ago - Lisata Therapeutics to be acquired by Kuva Labs for $5 per share cash plus CVR - TheFly
- 2 months ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 3 months ago - Lisata Therapeutics announces mutual termination of license agreement with Qilu - TheFly
- 3 months ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 4 months ago - Lisata Therapeutics downgraded to Hold from Buy at Brookline - TheFly
- 4 months ago - Lisata Therapeutics to be acquired by Kuva Labs for $4.00 per share - TheFly
- 4 months ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire